Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07052604

Enrollment

300

Registered

2025-07-04

Start date

2023-12-15

Completion date

2025-09-15

Last updated

2025-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-Bacterial Agents, Drug Resistance, Bacterial, Intensive Care Units, Pneumonia, Ventilator-Associated, Stenotrophomonas Maltophilia

Brief summary

This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. It compares using one antibiotic versus two antibiotics, and treatment lengths of 7 days versus 14 days, to see which approach helps patients survive better. The study also examines how resistant the bacteria are to antibiotics and how often the pneumonia comes back.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adult patients (age ≥ 18 years) * Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023 * Intubated and mechanically ventilated * Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia

Exclusion criteria

* Patients under 18 years old * Patients who refuse the use of their data for research purposes

Design outcomes

Primary

Measure	Time frame
patient survival based on the antibiotic treatment strategy used (monotherapy vs. combination therapy and 7 vs. 14 days duration).	28 days

Countries

France

Outcome results